Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors
作者:Joana Reis、Fernando Cagide、Martín Estrada Valencia、José Teixeira、Donatella Bagetta、Concepción Pérez、Eugenio Uriarte、Paulo J. Oliveira、Francesco Ortuso、Stefano Alcaro、María Isabel Rodríguez-Franco、Fernanda Borges
DOI:10.1016/j.ejmech.2018.07.056
日期:2018.10
was synthesized and screened towards human cholinesterases and monoamine oxidases. Compounds 2-(dimethylamino)ethyl (E)-3-(4-oxo-2-(p-methylphenlcarbamoyl)-4H-chromen-6-yl)acrylate (9a) and 2-(dimethylamino)ethyl (E)-3-(4-oxo-3-(phenylcarbamoyl)-4H-chromen-6-yl)acrylate (23a) were identified as the most promising multi-target inhibitors of the series. Compound 9a acted as a potent, selective and bifunctional
已经进行了大量的研究工作来设计用于治疗阿尔茨海默氏病(AD)的多靶点配体,这一方法因认识到AD是一种复杂而多因素的疾病而受到影响,这种疾病会影响许多与病理学途径相关的方法。因此,我们致力于开发基于色酮支架的多靶标配体。结果,合成了一个很小的色酮衍生物文库,并针对人胆碱酯酶和单胺氧化酶进行了筛选。化合物2-(二甲基氨基)乙基(E)-3-(4-氧代-2-(对甲基苯甲氨甲酰基)-4 H-铬烯-6-基)丙烯酸酯(9a)和2-(二甲基氨基)乙基(E)- 3-(4-氧代-3-(苯基氨基甲酰基)-4 H-铬-6-基)丙烯酸酯(23a)被鉴定为该系列中最有希望的多靶标抑制剂。化合物9a充当有效,选择性和双功能的AChEI(IC 50 = 0.21μM,K i = 0.19μM)并表现出双重h MAO抑制活性(h MAO-A IC 50 = 0.94μM,K i = 0.057μM和h MAO -B